

Application No. 10/699,882  
Amdt. dated August 22, 2005  
Reply to Office Action of May 9, 2005

4

Amendments to the Claims:

1. to 28. (Cancelled)

29. (Currently amended) A method of immunizing a host, which comprises:  
administering to the host an attenuated bacteria harbouring a vector  
comprising a nucleic acid molecule encoding at least one immunoprotection-  
inducing *Chlamydia* protein or a fragment thereof which generates a *Chlamydia*  
protein specific immune response and a promoter operatively coupled to said nucleic  
acid molecule for expression of said *Chlamydia* protein or fragment thereof by cells  
~~in cells~~ of the host but not by said in-said attenuated bacteria.

30. (Original) The method of claim 29 wherein said immunoprotection inducing  
*Chlamydia* protein or fragment thereof is a major outer membrane protein (MOMP)  
of a strain of *Chlamydia*.

31. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of  
*Chlamydia pneumoniae*.

32. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of  
*Chlamydia trachomatis*.

33. (Cancelled)

34. (Previously presented) The method of claim 29 wherein said promoter is a  
cytomegalovirus promoter.

35. (Previously presented) The method of claim 29 wherein said vector is a plasmid  
vector.

36. (Previously presented) The method of claim 35 wherein said plasmid vector is  
pcDNA3/MOMP as seen in Figure 5.

Application No. 10/699,882  
Amtd. dated August 22, 2005  
Reply to Office Action of May 9, 2005

5

37. (Original) The method of claim 29 wherein said attenuated bacteria is an attenuated strain of *Salmonella*.

38. (Original) The method of claim 37 wherein said attenuated strain of *Salmonella* is an attenuated strain of *Salmonella typhimurium*.

39. (Original) The method of claim 29 wherein said administration is effected to mucosal surfaces.

40. (Original) The method of claim 39 wherein said administration is effected by intranasal administration.